CYP2J3 gene delivery up-regulated adiponectin expression via reduced endoplasmic reticulum stress in adipocytes

Endocrinology

Volumn 154, Issue 5, 2013, Pages 1743-1753

  Xu, Xizhen ^a   Tu, Ling ^a   Feng, Wenjing ^a   Ma, Ben ^a   Li, Rui ^a   Zheng, Changlong ^a   Li, Geng ^a   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CYTOCHROME P450; CYTOCHROME P450 2J3; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; GENE TARGETING; GENETIC TRANSFECTION; INSULIN RESISTANCE; LIPID DIET; LIVER; MALE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; UPREGULATION;

3T3-L1 CELLS; ADIPOCYTES; ADIPONECTIN; ANIMALS; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; TRANSFECTION; UP-REGULATION;

EID: 84876771616     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-2012     Document Type: Article

References (36)

1. Xu X, Zhang XA, Wang DW. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev. 2011;63:597-609.
2. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.AmJ Physiol Renal Physiol. 2005; 289:F496-F503.
3. Xu X, Zhao CX, Wang L, et al. Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice. Diabetes. 2010;59:997-1005.
4. Xu X, Tu L, Wang L, Fang X, Wang DW. CYP2J3 gene delivery reduces insulin resistance via upregulation of eNOS in fructosetreated rats. Cardiovasc Diabetol. 2011;10:114.
5. Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci. 2009;30:234-239.
6. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439-451.
7. Wang C, Mao X, Wang L, et al. Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. J Biol Chem. 2007;282:7991-7996.
8. Choudhary S, Sinha S, Zhao Y, et al. NF-αB-inducing kinase (NIK) mediates skeletal muscle insulin resistance: blockade by adiponectin. Endocrinology. 2011;152:3622-3627.
9. Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-Activated protein kinase, p38 mitogen-Activated protein kinase, and peroxisome proliferator-Activated receptor -. Diabetes. 2006;55:2562-2570.
10. Luria A, Bettaieb A, Xi Y, et al. Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci USA. 2011;108: 9038-9043.
11. De Taeye BM, Morisseau C, Coyle J, et al. Expression and regulation of soluble epoxide hydrolase in adipose tissue. Obesity (Silver Spring). 2010;18:489-498.
12. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009;8: 794-805.
13. Deng Y, Theken KN, Lee CR. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol Cell Cardiol. 2010;48:331-341.
14. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 1999;6: 1258-1266.
15. Guo L, Zhou D, Pryse KM, Okunade AL, Su X. Fatty acid 2-hydroxylase mediates diffusional mobility of Raft-Associated lipids, GLUT4 level, and lipogenesis in 3T3-L1 adipocytes. J Biol Chem. 2010;285:25438-25447.
16. Zhao C, Wang P, Xiao X, et al. Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructoseinduced hypertensive rats. Hypertension. 2003;42:1026-1033.
17. ZhouL, LiuM,Zhang J, Chen H,DongLQ, Liu F. DsbA-L alleviates endoplasmic reticulum stress-induced adiponectin downregulation. Diabetes. 2010;59:2809-2816.
18. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-Acid oxidation by activating AMP-Activated protein kinase. Nat Med. 2002;8:1288-1295.
19. Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obes (Lond). 2009;33:54-66.
20. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860-867.
21. Hosogai N, Fukuhara A, Oshima K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007;56:901-911.
22. Han KL, Choi JS, Lee JY, et al. Therapeutic potential of peroxisome proliferators-Activated receptor-α/-dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes. Diabetes. 2008;57:737-745.
23. Liu M, Liu F. Transcriptional and post-translational regulation of adiponectin. Biochem J. 2010;425:41-52.
24. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002;51:2968-2974.
25. Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes. 2003;52:1655-1663.
26. Qiang L, Wang H, Farmer SR. Adiponectin secretion is regulated by SIRT1 and the endoplasmic reticulum oxidoreductase Ero1-L-.Mol Cell Biol. 2007;27:4698-4707.
27. Banga A, Unal R, Tripathi P, Pokrovskaya I, Owens RJ, Kern PA, Ranganathan G. Adiponectin translation is increased by the PPAR-Agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab. 2009;296:E480-E489.
28. Wray JA, Sugden MC, Zeldin DC, et al. The epoxygenases CYP2J2 activates the nuclear receptorPPAR-in vitro and in vivo.PLoSOne. 2009;4:e7421.
29. Liu Y, Zhang Y, Schmelzer K, et al. The antiinflammatory effect of laminar flow: the role of PPAR-, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci USA. 2005;102: 16747-16752.
30. Zhao G, Wang J, Xu X, et al. Epoxyeicosatrienoic acids protect rat hearts against tumor necrosis factor-α-induced injury. J Lipid Res. 2012;53:456-466.
31. Maeda N, Takahashi M, Funahashi T, et al. PPAR-ligands increase expression and plasma concentrations of adiponectin, an adiposederived protein. Diabetes. 2001;50:2094-2099.
32. Lobo SM, Quinto BM, Oyama L, et al. TNF-α modulates statin effects on secretion and expression of MCP-1, PAI-1 and adiponectin in 3T3-L1 differentiated adipocytes. Cytokine. 2012;60(1):150-156.
33. Komai N, Morita Y, Sakuta T, Kuwabara A, Kashihara N. Antitumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol. 2007;17:385-390.
34. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999; 285:1276-1279.
35. Deng Y, Edin ML, Theken KN, et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J. 2011;25: 703-713.
36. Liu Y, Dang H, Li D, Pang W, Hammock BD, Zhu Y. Inhibition of soluble epoxide hydrolase attenuates HF diet-induced hepatic steatosis by reduced systemic inflammatory status in mice. PLoS One. 2012;7:e39165.